Treatment of Olaparib-Induced Acute Myeloid Leukemia (AML)

Initial Assessment and Diagnosis

A complete diagnostic workup is essential, including peripheral blood and bone marrow examination with morphology, cytochemistry, immunophenotyping, cytogenetic and molecular analysis, according to the European Society for Medical Oncology 2
Risk stratification must consider both patient factors (age, performance status) and disease characteristics (leukocyte count, molecular markers), as recommended by the European Society for Medical Oncology 2
Pre-treatment cardiac assessment with echocardiography is recommended for patients with cardiac risk factors, according to the European Society for Medical Oncology 1

Standard induction therapy with 7 days of cytarabine and 3 days of an anthracycline (7+3 regimen) is recommended for eligible patients, according to the European Society for Medical Oncology 1, 2
Response assessment should be performed after hematological recovery or between days 28-35, as recommended by the European Society for Medical Oncology 2
Consolidation strategy depends on risk stratification, with favorable risk patients receiving high-dose cytarabine-based chemotherapy, and intermediate/adverse risk patients considering allogeneic stem cell transplantation, according to the European Society for Medical Oncology 1, 2

Options include clinical trials, intensive re-induction, allogeneic stem cell transplantation, and best supportive care, as recommended by the European Society for Medical Oncology 1, 2
Allogeneic stem cell transplantation should be considered for patients in second remission, according to the European Society for Medical Oncology 1, 2
Patients failing to respond to one or two cycles of induction treatment are considered refractory and may benefit from allogeneic stem cell transplantation if they have an HLA-matched donor, as recommended by the European Society for Medical Oncology 1

Bone marrow morphology should be evaluated every 3 months for 24 months, as recommended by the European Society for Medical Oncology 2
Differential blood counts should be monitored every 3 months for 5 years, according to the European Society for Medical Oncology 2
Molecular MRD assessment should be performed every 3 months from bone marrow or every 4-6 weeks from peripheral blood for 24 months in patients with a molecular marker, as recommended by the European Society for Medical Oncology 2

Treatment should be conducted in centers with multidisciplinary expertise and adequate infrastructure, according to the National Comprehensive Cancer Network 4
Clinical trials should be considered whenever possible, as recommended by the European Society for Medical Oncology 2

Supportive care is essential and should include prophylaxis and management of tumor lysis syndrome, infection, bleeding, and thrombosis, according to the European Society for Medical Oncology 2
Early mortality in AML is often related to bleeding, differentiation syndrome, or infection rather than disease progression, as noted by the National Comprehensive Cancer Network 5